NEW ORLEANS—More is better, at least when it comes to treatments for multiple myeloma. Separate studies from a Spanish group and an Italian group showed that up-front use of four drugs improves durable responses and progression-free survival in elderly patients. Both studies also showed that a kinder, gentler weekly schedule of bortezomib (Velcade) instead of the standard twice-weekly schedule maintains efficacy and reduces toxicity.
NEW ORLEANS—A new treatment for patients who are severely debilitated by myelofibrosis offers hope of a return to normal daily life. Preliminary studies with an oral drug INCB018424 that targets the Janus-activated kinase (JAK) 2 gene appears to markedly reduce the swelling of the spleen and sometimes the liver, which can, in turn, can change patients’ quality of life.
NEW ORLEANS—There was good news at ASH 2009 on promising treatments for indolent lymphoma and aggressive non-Hodgkin’s lymphoma. Also, a separate poster presentation showed that even just one cycle of post-remission therapy extended survival in elderly patients with acute myeloid leukemia.
NEW ORLEANS—The scientific program sessions are a unique offering at ASH, with an agenda that varies from the overall meeting. First, the speakers are invited to share their particular expertise with ASH attendees. Also, the abstracts are not peer-reviewed but are crafted specifically for the meeting.